PURPOSE: Experimental and epidemiological evidence shows a beneficial role of vitamin D in cancer. In vitro evidence is consistent with a similar protective function in glioma; however, no study has yet examined the potential role of vitamin D in glioma. METHODS: We evaluated the association between common genetic variants in the vitamin D pathway and glioma risk and patient outcome in 622 newly diagnosed glioma cases and 628 healthy controls enrolled in a clinic-based case-control study. Subjects were genotyped for 7 candidate and tagging single nucleotide polymorphisms in the vitamin D receptor and 8 additional variants in NADSYN1, GC, CYP24A1, CYP2R1, and C10ORF88 linked in genome-wide association studies to serum concentrations of vitamin D. Unconditional logistic regression was used to estimate age- and gender-adjusted odds ratios and 95 % confidence intervals for glioma risk according to vitamin D genotypes. Proportional hazards regression was used to estimate hazard ratios for glioma-related death among 320 patients diagnosed with high-grade tumors. P values were uncorrected for multiple comparisons. RESULTS: Risk of astrocytic tumors was associated with variant alleles in rs3829251 (NADSYN1), rs10741657 (CYP2R1), rs2228570 (Fok1, VDR), and rs731236 (Taq1, VDR). No risk associations were found among oligodendroglial tumors. Survival associations were observed according to variant status for rs1544410 (Bsm1, VDR) and rs6013897 (CYP24A1). CONCLUSION: This exploratory analysis provides limited evidence of a role for genetic variation in vitamin D pathway genes with glioma risk and survival.
PURPOSE: Experimental and epidemiological evidence shows a beneficial role of vitamin D in cancer. In vitro evidence is consistent with a similar protective function in glioma; however, no study has yet examined the potential role of vitamin D in glioma. METHODS: We evaluated the association between common genetic variants in the vitamin D pathway and glioma risk and patient outcome in 622 newly diagnosed glioma cases and 628 healthy controls enrolled in a clinic-based case-control study. Subjects were genotyped for 7 candidate and tagging single nucleotide polymorphisms in the vitamin D receptor and 8 additional variants in NADSYN1, GC, CYP24A1, CYP2R1, and C10ORF88 linked in genome-wide association studies to serum concentrations of vitamin D. Unconditional logistic regression was used to estimate age- and gender-adjusted odds ratios and 95 % confidence intervals for glioma risk according to vitamin D genotypes. Proportional hazards regression was used to estimate hazard ratios for glioma-related death among 320 patients diagnosed with high-grade tumors. P values were uncorrected for multiple comparisons. RESULTS: Risk of astrocytic tumors was associated with variant alleles in rs3829251 (NADSYN1), rs10741657 (CYP2R1), rs2228570 (Fok1, VDR), and rs731236 (Taq1, VDR). No risk associations were found among oligodendroglial tumors. Survival associations were observed according to variant status for rs1544410 (Bsm1, VDR) and rs6013897 (CYP24A1). CONCLUSION: This exploratory analysis provides limited evidence of a role for genetic variation in vitamin D pathway genes with glioma risk and survival.
Authors: Sharif B Mohr; Edward D Gorham; Cedric F Garland; William B Grant; Frank C Garland Journal: Neuroepidemiology Date: 2010-10-14 Impact factor: 3.282
Authors: Yue Fang; Joyce B J van Meurs; Arnold d'Alesio; Mila Jhamai; Hongyan Zhao; Fernando Rivadeneira; Albert Hofman; Johannes P T van Leeuwen; Frédéric Jehan; Huibert A P Pols; André G Uitterlinden Journal: Am J Hum Genet Date: 2005-09-26 Impact factor: 11.025
Authors: Kim Köstner; Nicole Denzer; Cornelia S L Müller; Rolf Klein; Wolfgang Tilgen; Jörg Reichrath Journal: Anticancer Res Date: 2009-09 Impact factor: 2.480
Authors: Sanjay Shete; Fay J Hosking; Lindsay B Robertson; Sara E Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean-Yves Delattre; Khe Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu; Ching Lau; Minouk Schoemaker; Kenneth Muir; Anthony Swerdlow; Mark Lathrop; Melissa Bondy; Richard S Houlston Journal: Nat Genet Date: 2009-07-05 Impact factor: 38.330
Authors: Josef Elias; Brigitte Marian; Christa Edling; Bodo Lachmann; Christian R Noe; Schulte-Hermann Rolf; Inge Schuster Journal: Recent Results Cancer Res Date: 2003
Authors: John R Davies; Yu-Mei Chang; Helen Snowden; May Chan; Susan Leake; Birute Karpavicius; Sue Haynes; Kairen Kukalizch; Juliette Randerson-Moor; Faye Elliott; Julian Barth; Peter A Kanetsky; Mark Harland; D Timothy Bishop; Jennifer H Barrett; Julia A Newton-Bishop Journal: Cancer Causes Control Date: 2011-08-19 Impact factor: 2.506
Authors: Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke Journal: Nat Genet Date: 2009-07-05 Impact factor: 38.330
Authors: Débora G Salomón; María E Fermento; Norberto A Gandini; María J Ferronato; Julián Arévalo; Jorge Blasco; Nancy C Andrés; Jean C Zenklusen; Alejandro C Curino; María M Facchinetti Journal: J Neurooncol Date: 2014-03-01 Impact factor: 4.130
Authors: Irene Orlow; Anne S Reiner; Nancy E Thomas; Pampa Roy; Peter A Kanetsky; Li Luo; Susan Paine; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Stefano Rosso; Roberto Zanetti; Stephen B Gruber; Hoda Anton-Culver; Richard P Gallagher; Terence Dwyer; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Carcinogenesis Date: 2015-10-31 Impact factor: 4.944